Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).
Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer
OTHER: No intervention
Percentage of Adverse Events (AEs), From baseline to end of study up to 18 months|Percentage of Serious Adverse Events (SAEs), From baseline to end of study up to 18 months
Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).